ResearcherMerrimack Pharmaceuticals (United States)No recent work listed

Adam J. Camblin

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5032545251. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2018: 1 paper

Papers 1

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-2262 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Chrystal Ursula Louis · 1 shared paper, 2018 · strength 0.06
- Paper Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pa… DOI 10.1158/1078-0432.ccr-17-2262 ↗
Alexey A. Lugovskoy · 1 shared paper, 2018 · strength 0.06
- Paper Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pa… DOI 10.1158/1078-0432.ccr-17-2262 ↗
Robert M. Straubinger · 1 shared paper, 2018 · strength 0.06
- Paper Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pa… DOI 10.1158/1078-0432.ccr-17-2262 ↗
J. Marc Pipas · 1 shared paper, 2018 · strength 0.06
- Paper Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pa… DOI 10.1158/1078-0432.ccr-17-2262 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.